NMNH (Reduced NMN) · Tier C Emerging Research Compound

1. Three Questions in Sixty Seconds

1.1 What is NMNH?

NMNH is the reduced form of NMN. Chemically, it is NMN with two additional hydrogens at the nicotinamide ring — the same redox relationship that distinguishes NADH from NAD+, applied at the mononucleotide level instead of the dinucleotide level. Aliases used in the literature include reduced NMN, NMN-H, dihydroNMN, and dihydronicotinamide mononucleotide.

NMNH sits at the same level of the NAD+ precursor hierarchy as NMN, NR, niacinamide, and niacin, but in the "reduced" family alongside NRH (the reduced form of NR). The reduced family is a newer research subject — the oxidised precursors (NR, NMN, niacin, niacinamide) have decades of cumulative research; the reduced precursors emerged into the research literature only after 2020.

1.2 Is NMNH "more powerful" than NMN?

In hepatocyte cell culture and mouse liver tissue, NMNH elevates intracellular NAD+ more efficiently than equimolar NMN — three independent preclinical studies report this (Liu 2021 PMID 33793246, Zapata-Pérez 2023 PMID 36869544, Vinten 2026 PMID 41701114). However, three substantial caveats must travel with that statement:

1. All of this evidence is preclinical (cell culture and mouse liver) — none of it is from humans.
2. NMNH simultaneously raises the NADH pool, which NMN does not. The physiological consequences of this dual-pool elevation in humans are unknown.
3. Vinten 2026 (FASEB J, 28 February 2026) reported that NMNH triggers a glutathione-S-transferase family transcriptional pseudo-stress signal in hepatocytes that NMN does not. Whether this is beneficial adaptation or hepatic warning is not yet known.

1.3 Can I buy NMNH as a supplement?

As of 2026-05-26, ASXAN does not recommend NMNH for routine consumer supplementation. The reasons are cumulative:

• Zero human clinical trials in PubMed, ClinicalTrials.gov, and the EU Clinical Trials Register
• Zero human safety data of any duration
• Zero published dose-exploration studies — any product claiming a daily NMNH dose is doing so without RCT support
• Zero NDI notifications, GRAS notifications, or IND applications received by the FDA
• Zero Novel Food applications in the EFSA OpenEFSA system
• Zero approval pathway in the ANVISA framework

For consumers seeking NAD+ support today, the evidence-supported options are NMN (United States DSHEA legal status restored on 29 September 2025), NR (US GRAS, EU Novel Food partial), and NADH (decades of human safety and modest randomised efficacy data in chronic fatigue and jet-lag cognition).

2. Chemical Identity and Origin

2.1 Identity card

2.2 The 2021 clean-synthesis paper — the origin point

Before 2021, NMNH appeared in textbooks as a transient metabolic intermediate but had not been purified, characterised, and made available as a research-grade compound. Liu Y, Luo C, Li T, Zhang W, Zong Z, Liu X, Deng H, of Tsinghua University, published the first clean chemical synthesis in Journal of Proteome Research on 7 May 2021 (PMID 33793246). This paper is the origin point for every subsequent NMNH study.

2.3 The 2023 biocatalysis routes — from bench to scalable production

Two independent enzymatic and biocatalytic routes appeared in 2023:

• Zapata-Pérez R et al. 2023 (Murcia Catholic University and Amsterdam UMC, Food Research International, PMID 36869544): a three-enzyme cascade that produces six NAD+ precursors (NMN, NR, NMNH, NRH, NaMN, NaR) from NAD+ and NADH starting materials.
• Liu Y et al. 2023 (Jiangnan University and Seragon Biosciences, Frontiers in Bioengineering and Biotechnology, PMID 37082214): a protein-engineered E. coli NADH pyrophosphatase (EcNudc-M) reaching a 16.65 g/L NMNH titre in a 7-litre fermenter. This is the first publicly reported NMNH biocatalysis route at industrial-scale-relevant titre.

These two papers established that NMNH can be produced as a research-grade or industrial-intermediate material. Neither paper, however, constitutes regulatory authorisation for use of NMNH in dietary supplements; the FDA, EFSA, and ANVISA have all received zero applications for NMNH as a food or food-ingredient material as of 2026-05-26.

3. How NMNH Behaves in Cells — and How It Differs from NMN

3.1 Cell entry — NMN and NMNH do not use identical routes

NMN (oxidised) is widely thought to enter cells either through the disputed SLC12A8 transporter (Grozio 2019 Nature Metabolism, contested by Schmidt and Brenner 2020) or via intestinal dephosphorylation to NR followed by ENT-mediated nucleoside uptake and intracellular NRK1-mediated rephosphorylation. NMNH (reduced) appears to follow a different biochemical route: Liu 2021 (PMID 33793246) reported that NMNH is converted to NAD+ by NMNAT enzymes in cell-free experiments with comparable or higher catalytic efficiency than NMN, and in hepatocyte culture and mouse liver tissue NMNH elevates the intracellular NAD+ pool while simultaneously elevating the NADH pool.

3.2 Vinten 2026 — the four-precursor multi-omics comparison

Vinten KT, Schomakers BV, Denis S, van Weeghel M, Jongejan A, Ofman R, Piersma SR, Jimenez CR, Janssens GE, Zapata-Pérez R, Houtkooper RH (Amsterdam UMC and Murcia Catholic University, FASEB Journal, 28 February 2026, PMID 41701114) is the most authoritative cell-characterisation study of NMNH to date. They compared NMN, NMNH, NR, and NRH side by side in mouse primary hepatocytes using RNA-sequencing, proteomics, and metabolomics.

The Vinten 2026 abstract concludes that "reduced NAD+ precursors are unique and distinct from the market-available NAD+ precursors NR and NMN, not only as more potent NAD+ boosters, but also as compounds influencing a broader range of cellular processes." Translation: the reduced precursors (NMNH and NRH) leave a broader transcriptional, proteomic, and metabolomic footprint in hepatocytes than the oxidised precursors do. Whether that broader footprint is a feature or a risk has not been adjudicated.

3.3 The "yellow flag" preclinical observations from Liu 2021

Liu 2021 (PMID 33793246) also reported, in cultured cells, that NMNH suppressed glycolysis and the TCA cycle in metabolomic profiling, induced cell-cycle arrest and inhibited cell proliferation in culture, and produced no body-weight changes in short-term mouse exposure (with no long-term mouse data). The "raises NAD+ but also suppresses glycolysis and stops cells dividing" combination is mechanistically novel — but it raises a question that no preclinical study can answer: what happens when this is given orally to a human whose haematopoietic, gut-mucosal, skin, and wound-healing tissues all depend on active cell division? The answer requires a Phase I human safety trial, which has not been conducted.

4. The Evidence Gap — Why NMNH Is Tier C and NMN Is Tier A/B

4.1 Endpoint-by-endpoint comparison

4.2 Hard editorial rails for this Tier C page

1. No human efficacy claim of any kind — including cognition, energy, longevity, athletic performance, or sleep — is made on this page. Zero human evidence supports any such claim.
2. No dose recommendation is made on this page. Any product page that prints "NMNH 250 mg/day" or "NMNH 500 mg/day" is doing so without RCT support.
3. No safety reassurance is made on this page. The preclinical cell-cycle arrest and Gst pseudo-stress observations are real findings in the published literature and require human dose-exploration studies before "well tolerated" language can be used.
4. No "better than NMN" consumer-level comparison is made on this page. The preclinical efficiency difference is real in hepatocytes and mouse liver, but a consumer-level superiority claim requires head-to-head human trials, which have never been performed.

4.3 The one defensible summary sentence

NMNH is a research-stage reduced NAD+ precursor that has shown preclinical NAD+-elevation efficiency advantages and broader hepatocyte transcriptomic footprint than NMN, but until human safety, pharmacokinetic, or efficacy studies appear, it does not constitute a defensible consumer supplement choice.

5. Safety — The Honest Tier C Section

5.1 Banner

5.2 Preclinical signals to keep in mind (not consumer reassurance)

• Cell-cycle arrest in cultured cells treated with NMNH (Liu 2021). Consequences for human haematopoiesis, gut-mucosal turnover, skin renewal, and wound healing are unknown.
• Glycolysis and TCA-cycle suppression in cultured cells (Liu 2021). Consequences for athletes, individuals undergoing fasting, and during immune-cell activation are unknown.
• Gst-family pseudo-stress signal in mouse hepatocytes (Vinten 2026 PMID 41701114). Consequences in humans, particularly in individuals with elevated baseline oxidative stress, are unknown.

5.3 Comparison with NMN safety

NMN has multiple ≥12-week human RCTs, a single-dose escalation up to 1250 mg/day for four weeks (Fukamizu 2022 PMID 36002548), and partial long-term safety data — the standard threshold for dietary-supplement safety discussion. NMNH has none of those.

6. Regulatory Status — Three Markets, All Unauthorised

This page focuses on the three regulatory markets within the asxan.ai international scope: the United States (FDA), the European Union (EFSA), and Brazil (ANVISA).

6.1 United States · FDA · Silent · Unregistered New Substance

• NDI database 2026-05-26: zero NMNH submissions
• GRAS self-certifications or notifications: zero for NMNH
• IND filings: zero publicly searchable for NMNH
• The September 2025 NMN reversal does not extend to NMNH automatically: the FDA's analysis was specific to the NMN chemical entity, and NMNH is a distinct chemical entity that would require its own NDI, GRAS, or IND pathway.

6.2 European Union · EFSA · No Novel Food Application

• EFSA OpenEFSA registration system 2026-05-26: zero Novel Food applications for NMNH
• Under EU Novel Food regulation, any food ingredient not significantly consumed in the EU before 15 May 1997 must complete EFSA evaluation and European Commission authorisation before being sold as a food or food ingredient
• NMNH has neither historical pre-1997 consumption nor an NFA application — it cannot be sold as a food or food ingredient in the European Union

6.3 Brazil · ANVISA · Undefined · No Precedent

• Under the current Brazilian framework (RDC 243/2018 for dietary supplements, IN 28/2018 for claims), NMNH is an undefined novel substance requiring case-by-case ingredient evaluation
• NMN itself has no current authorised claims in Brazil and is under the RE 1139/2022 full-chain prohibition; NMNH inherits a similarly restrictive baseline
• Any NMNH-containing product launching in Brazil would require its own ANVISA registration pathway

6.4 One-sentence summary

All three markets in scope are silent, unauthorised, or undefined for NMNH as of 2026-05-26 — there is no pending NMNH application currently in review in any of the three frameworks.

7. Who Might Read This Page

These short sections frame NMNH for different reader interests — they are not recommendations. The recommendation in 2026 across every reader profile is the same: consider NMN, NADH, or the cluster hub's evidence-supported options first.

7.1 The longevity stack research follower

NMNH joins the NR / NMN / NRH "reduced-and-oxidised NAD+ precursor four-piece set". It is the family member with the thinnest clinical evidence — strong preclinical data, zero human RCTs. If you are tracking the field, NMNH belongs on a research watchlist, not on a supplement-stack list.

7.2 The cognitive support explorer

NAD+ is central to neuronal energy metabolism, and the question of whether reduced precursors cross the blood-brain barrier more readily than oxidised precursors is an interesting preclinical question. Zero human cognitive-endpoint NMNH data exist as of 2026.

7.3 The athletic performance reader and the athletic performance lifestyle

NMN has human RCT support in amateur runners (Liao 2021). NMNH has zero human exercise data. Additional consideration: the Liu 2021 glycolysis suppression signal in cultured cells is a flag for high-intensity training contexts that depend on glycolytic ATP — until human dose-exploration studies clarify whether this transfers to athletes, NMN remains the evidence-supported choice for performance.

7.4 The heart health reader

2024 Cell Communication and Signaling review (PMID 39516787) discusses NAD+ enhancers in the cardiorenal axis; NMNH is mentioned in passing only, and zero human cardiac endpoint data exist.

7.5 The senior 60+ reader

The age-related NAD+ decline rationale applies in principle to NMNH as much as to NMN, but the principle does not substitute for clinical evidence. Until an NMNH safety trial completes in any older adult population, older adults are precisely the cohort that should not be NMNH's first consumer base — counterintuitive but evidence-aligned.

7.6 The high-stress lifestyle reader

Vinten 2026 reported the Gst-family pseudo-stress signal in hepatocytes — a transcriptional pattern that resembles a response to oxidative stress without depleting glutathione. For readers with already-elevated baseline oxidative stress (chronic high-load contexts), this signal is a flag, not a reassurance.

7.7 The intermittent fasting practitioner

Fasting endogenously elevates NAD+ via NAMPT activation. Whether exogenous NMNH would synergise, antagonise, or have no interaction with intermittent fasting is unknown — no preclinical or clinical study has tested it.

8. Open Questions on the Research Watchlist

1. First registered human Phase I trial. ClinicalTrials.gov and EU Clinical Trials Register both at zero as of 2026-05-26. This is the most important first milestone.
2. Oral pharmacokinetics and bioavailability. Reduced precursors may be more susceptible to gastric acid than oxidised precursors.
3. Long-term meaning of the Gst pseudo-stress signal. Beneficial adaptation or hepatic warning? A 90-day-plus animal or human study is needed.
4. Translation of the glycolysis-suppression signal. What happens in human skeletal muscle, activated immune cells, and healing tissues?
5. NMNH vs NRH "reduced precursor race". Which reaches clinical development first?
6. First regulatory pathway opening. FDA NDI, GRAS, IND, EU NFA, or ANVISA — whichever opens first will set the consumer-access timeline.

Related Goals and Lifestyles

References (7 PMIDs · all preclinical · zero human RCTs)

1. PMID 33793246 · Liu Y, Luo C, Li T, Zhang W, Zong Z, Liu X, Deng H. 2021. "Reduced Nicotinamide Mononucleotide (NMNH) Potently Enhances NAD+ and Suppresses Glycolysis, the TCA Cycle, and Cell Growth." J Proteome Res. The first clean chemical synthesis; cell culture and acute mouse exposure data.
2. PMID 41701114 · Vinten KT et al. 2026. "Reduced Versus Oxidized NAD+ Precursors Drive Distinct Transcriptomic, Proteomic, and Metabolic Profiles in Hepatocytes." FASEB J (28 February 2026). Four-precursor mouse hepatocyte multi-omics comparison; Gst pseudo-stress signal in reduced precursors.
3. PMID 36869544 · Zapata-Pérez R et al. 2023. "Biotechnological production of reduced and oxidized NAD+ precursors." Food Res Int. Three-enzyme cascade producing six NAD+ precursors.
4. PMID 37082214 · Liu Y et al. 2023. "Protein engineering of NADH pyrophosphatase for efficient biocatalytic production of reduced nicotinamide mononucleotide." Front Bioeng Biotechnol. 7-litre fermenter, 16.65 g/L NMNH titre.
5. PMID 34553119 · Palmer RD, Elnashar MM, Vaccarezza M. 2021. "Precursor comparisons for the upregulation of nicotinamide adenine dinucleotide. Novel approaches for better aging." Aging Med (Milton). NR/NMN/NMNH/DNR comparison review. Disclosed conflict of interest: first author is CSO of Helium-3 Biotech.
6. PMID 37447389 · Dhuguru J, Dellinger RW, Migaud ME. 2023. "Defining NAD(P)(H) Catabolism." Nutrients. Confirms NMNH and NRH "increase NAD+ levels, although administration initially yields NADH (the reduced form of NAD+)." Disclosed conflict of interest: two authors funded by Elysium Health.
7. PMID 36524597 · Smolin AG. 2022. "Ab Initio Studies of NMNH(2−) Conformers in Water-Methanol Solutions." J Phys Chem B. Computational confirmation of solution-state ionic form.

Educational Disclaimer · Reader to 2030

This page is educational reference content and is not medical advice. NMNH is a Tier C emerging research compound with zero human clinical trial evidence as of 2026-05-26 and is not appropriate as a routine dietary supplement. If you are reading this page in a future year and NMNH has acquired human RCT data, FDA NDI status, or authorisation in the European Union or Brazil, please refer to ASXAN's then-current page; the content here is dated 2026-05-26.